Outlook Therapeutics ( ($OTLK) ) has released its Q1 earnings. Here is a breakdown of the information Outlook Therapeutics presented to its ...
Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...
Research Triangle Park, North Carolina Saturday, February 15, 2025, 17:00 Hrs [IST] ...
Hosted on MSN20h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPCAdding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback